A nurse is educating a patient who has been prescribed Haloperidol about the risk of extrapyramidal symptoms. Which of the following statements by the patient indicates a need for further teaching?

A. 100 mg:. The label clearly states that each capsule contains 25 mg of Indomethacin. There is no indication that multiple capsules are taken at once unless prescribed, so 100 mg is incorrect for a single capsule dosage.
B. 125 mg: This is not the indicated dose per capsule.
C. 25 mg: The label clearly indicates that each capsule contains 25 mg of Indomethacin. This is the correct dosage per capsule. Indomethacin is often available in 25 mg increments for safe titration and individualized dosing based on patient need.
D. 75 mg: While 75 mg is a common dosage form for some extended-release Indomethacin preparations, this particular label shows 25 mg immediate-release capsules. There is no mention of 75 mg on the drug label in this case.

A. Donepezil cures Alzheimer's disease: There is currently no cure for Alzheimer's disease. Donepezil does not halt or reverse the disease process; it only manages symptoms for a limited period in some patients.
B. Donepezil prevents the progression of Alzheimer’s disease: Donepezil does not prevent the neurodegenerative progression of Alzheimer’s. The disease will continue to advance despite treatment, although symptoms may be temporarily improved.
C. Donepezil reverses Alzheimer’s disease: Alzheimer's-related brain damage is irreversible, and Donepezil cannot regenerate lost neurons or restore lost function. It may slightly improve cognitive function but cannot reverse the disease process.
D. Donepezil provides symptom relief for Alzheimer’s disease: Donepezil is a cholinesterase inhibitor that increases acetylcholine levels in the brain, temporarily improving cognitive symptoms like memory and awareness. It is approved for symptom management, especially in mild to moderate stages.